ARS Pharmaceuticals, Inc. — Director's Dealing 2022

Nov 11, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2022-11-08

Reporting Person: Kelly Michael (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-11-08	Common Stock	A	83225	—	Acquired	83225	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-11-08	Employee Stock Option (right to buy)	$0.84	A	70422	Acquired	2029-07-04	Common Stock (70422)	Direct
2022-11-08	Employee Stock Option (Right to Buy)	$1.44	A	118190	Acquired	2031-12-13	Common Stock (118190)	Direct

Footnotes

F1: Received in exchange for 70,416 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of ARS common stock was converted into the right to receive 1.1819 shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc.

F2: The Reporting Person's spouse and sister are trustees of the trust. The beneficiary of the trust is the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these Securities for purposes of Section 16 or for any other purpose.

F3: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured the first anniversary of the vesting commencement date.

F4: Received in exchange for a stock option to acquire 59,584 shares of common stock of ARS pursuant to the Merger Agreement.

F5: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F6: The shares vest in a series of thirty-six (36) successive equal monthly installments measured from the vesting commencement date.

F7: Received in exchange for a stock option to acquire 100,000 shares of common stock of ARS pursuant to the Merger Agreement.